BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); breast cancer; small cell lung cancer A University of Florida team led by Dialectic Therapeutics Inc. co-founders Guangrong Zheng and Daohong Zhou showed the company’s lead candidate,...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

New targeted lung cancer therapies against RET, KRAS and c-MET are all outperforming standard of care in the clinic, including checkpoint inhibitors. But whether these therapies see uptake will likely depend more on whether next-generation...
BC Innovations | Aug 22, 2019
Translation in Brief

Systems biology orders strategy to avoid cross-drug resistance in cancer

A Harvard and Mitra Biotech team used systems biology to identify a temporal treatment regimen that uses a glucose metabolism inhibitor to overcome cross-drug resistance in breast cancer. Chemotherapies are often administered in combination regimens...
BioCentury | Jun 1, 2019
Product Development

Clinical trial and regulatory efficiency get help from ctDNA, RWE at ASCO19

This year’s crop of ASCO abstracts show companies are going full bore on pre- and post-market technologies that can speed up development and regulatory timelines. In BioCentury’s analysis of 4,627 abstracts, over 500 feature circulating...
BC Week In Review | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

Merrimack discontinued development of MM-310 -- the company's last remaining product in clinical testing -- after a safety update showed that a Phase I trial in solid tumor patients "would not be able to reach...
BC Week In Review | Mar 15, 2019
Clinical News

Lilly looks to expand Cyramza's label into first-line NSCLC

Eli Lilly said it plans to initiate global regulatory applications mid-year seeking to expand the label of Cyramza ramucirumab to include first-line treatment of metastatic non-small cell lung cancer in patients whose tumors have activating...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
BC Innovations | Feb 6, 2019
Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...
BC Week In Review | Feb 1, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...
BC Extra | Jan 30, 2019
Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...
Items per page:
1 - 10 of 1597